WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2019> 25> 3

Volume: 25 Issue: 3

1. Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease Page:331—332
2. Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report Page:326—330
3. Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis? Page:317—325
4. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio Page:305—316
5. Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes Page:294—304
6. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir Page:283—293
7. How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? Page:280—282
8. Sarcopenia: Ammonia metabolism and hepatic encephalopathy Page:270—279
9. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Page:264—269
10. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update Page:245—263
11. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C Page:234—244
12. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers Page:223—233

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.